

BIOTECHNOLOGY FUND

	SHARES	VALUE		SHARES	VALUE
COMMON STOCKS[†] - 99.7%					
BIOTECHNOLOGY - 75.5%					
Amgen, Inc.	30,526	\$ 6,880,561			
Vertex Pharmaceuticals, Inc.*	19,420	5,622,867			
Gilead Sciences, Inc.	91,059	5,617,430			
Regeneron Pharmaceuticals, Inc.*	8,029	5,530,937			
Biogen, Inc.*	17,196	4,591,332			
Moderna, Inc.*	34,376	4,064,962			
Corteva, Inc.	70,979	4,056,450			
Illumina, Inc.*	17,908	3,416,667			
Royalty Pharma plc — Class A	77,596	3,117,807			
Seagen, Inc.*	22,611	3,093,863			
Alnylam Pharmaceuticals, Inc.*	15,271	3,056,643			
BioMarin Pharmaceutical, Inc.*	29,334	2,486,643			
Incyte Corp.*	36,488	2,431,560			
Horizon Therapeutics plc*	38,687	2,394,339			
Biohaven Pharmaceutical Holding Company Ltd.*	14,318	2,164,452			
Sarepta Therapeutics, Inc.*	17,815	1,969,270			
United Therapeutics Corp.*	9,387	1,965,450			
BioNTech SE ADR	13,818	1,863,772			
Apellis Pharmaceuticals, Inc.*	26,729	1,825,591			
CRISPR Therapeutics AG*	25,908	1,693,088			
Ionis Pharmaceuticals, Inc.*	36,295	1,605,328			
Halozyne Therapeutics, Inc.*	37,908	1,498,882			
Guardant Health, Inc.*	27,255	1,467,137			
Global Blood Therapeutics, Inc.*	20,752	1,413,211			
Exelixis, Inc.*	88,121	1,381,737			
Cytokinetics, Inc.*	27,268	1,321,135			
ChemoCentryx, Inc.*	24,470	1,264,120			
Intellia Therapeutics, Inc.*	22,571	1,263,073			
Denali Therapeutics, Inc.*	41,100	1,261,359			
Blueprint Medicines Corp.*	18,462	1,216,461			
Mirati Therapeutics, Inc.*	16,901	1,180,366			
Arrowhead Pharmaceuticals, Inc.*	34,490	1,139,895			
Beam Therapeutics, Inc.*	22,944	1,093,052			
Ultragenyx Pharmaceutical, Inc.*	24,697	1,022,703			
BioCryst Pharmaceuticals, Inc.*	77,429	975,605			
Fate Therapeutics, Inc.*	38,633	865,766			
Twist Bioscience Corp.*	23,472	827,153			
Iovance Biotherapeutics, Inc.*	78,008	747,317			
Veracyte, Inc.*	39,120	649,392			
NeoGenomics, Inc.*	72,438	623,691			
Emergent BioSolutions, Inc.*	29,181	612,509			
Novavax, Inc.*	32,604	593,393			
Editas Medicine, Inc.*	43,164	528,327			
Total Biotechnology		<u>92,395,296</u>			
PHARMACEUTICALS - 16.4%					
AbbVie, Inc.	73,391	9,849,806			
AstraZeneca plc ADR	66,089	3,624,321			
Neurocrine Biosciences, Inc.*	19,673	2,089,469			
Viatis, Inc.	230,233	1,961,585			
Jazz Pharmaceuticals plc*	12,765	1,701,447			
Ironwood Pharmaceuticals, Inc. — Class A*	77,515	803,056			
Total Pharmaceuticals		<u>20,029,684</u>			
HEALTHCARE-PRODUCTS - 4.3%					
Bio-Techne Corp.	6,989	\$ 1,984,876			
Exact Sciences Corp.*	43,377	1,409,319			
Natera, Inc.*	28,141	1,233,138			
CareDx, Inc.*	34,657	589,862			
Total Healthcare-Products		<u>5,217,195</u>			
HEALTHCARE-SERVICES - 3.5%					
ICON plc*	8,701	1,599,070			
Medpace Holdings, Inc.*	9,101	1,430,404			
Syneos Health, Inc.*	26,788	1,263,054			
Total Healthcare-Services		<u>4,292,528</u>			
Total Common Stocks					
(Cost \$70,150,002)					<u>121,934,703</u>
			FACE		
			AMOUNT		
REPURCHASE AGREEMENTS^{††,1} - 0.7%					
J.P. Morgan Securities LLC issued 09/30/22 at 2.97% due 10/03/22			\$ 488,926		488,926
BofA Securities, Inc. issued 09/30/22 at 2.91% due 10/03/22			188,048		188,048
Barclays Capital, Inc. issued 09/30/22 at 2.92% due 10/03/22			182,482		182,482
Total Repurchase Agreements					<u>859,456</u>
(Cost \$859,456)					
Total Investments - 100.4%					<u>\$ 122,794,159</u>
(Cost \$71,009,458)					
Other Assets & Liabilities, net - (0.4)%					<u>(457,190)</u>
Total Net Assets - 100.0%					<u>\$ 122,336,969</u>

BIOTECHNOLOGY FUND

* Non-income producing security.

† Value determined based on Level 1 inputs.

†† Value determined based on Level 2 inputs.

¹ Repurchase Agreements.

ADR — American Depositary Receipt

plc — Public Limited Company